News
MedPage Today on MSN2d
Zepbound and Wegovy Go Head to Head for Obesity: And the Winner Is ...Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...
CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...
InvestorsHub on MSN12h
Novo Nordisk Inks $2.2 Billion Deal with Septerna to Advance Obesity and Diabetes TreatmentsNovo Nordisk (NYSE: NVO) has entered into a collaboration and licensing agreement with U.S.-based biotech firm Septerna ...
"These data confirm Zepbound as a leading treatment option for people living with obesity and equip healthcare ...
Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.
President Trump said he would sign an executive order to base U.S. drug prices on what other countries pay — usually far less ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback